Laekna, Inc. (HK:2105) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Laekna, Inc. has successfully dosed all subjects in its Phase I clinical trial of LAE102, aimed at treating obesity. Early results show promising safety and biomarker changes, signaling progress in their innovative weight control therapy. The company plans to proceed with further trials while maintaining strong financial discipline to support its clinical advancements.
For further insights into HK:2105 stock, check out TipRanks’ Stock Analysis page.